Clinical Advances in Understanding HER2 - A Cornerstone of Breast Cancer Therapy

The HER2 protein is overexpressed in 20 to 30% of breast cancers, and recent advances in HER2-directed therapies have revolutionized the treatment of HER2-positive breast cancer in both the early (adjuvant) and advanced (metastatic) settings. However, the HER2 field continues to evolve with the development of various HER2-targeted therapies that will address issues such as treatment resistance, optimal treatment paradigms, and patient quality of life.

HER2+ Breast Cancer: Updating Current Best Practice
Watch this case-based discussion led by Dr Gelmon on the clinical application of recent data from trials evaluating targeted agents in HER2-positive breast cancer.
January 4, 2016

Steering Committee Chair

Karen A. Gelmon, MD
Professor of Medicine,
University of British
Columbia Medical Oncologist,
British Columbia Cancer Agency
Vancouver Cancer Centre,
Clinical Head Investigational
Drug Program Experimental Therapeutics,
British Columbia Cancer Research Centre,
Vancouver, Canada

Steering Committee Members

Carlos H. Barrios, MD
Professor, Internal Medicine Department, PUCRS School of Medicine; Director, Oncology Research Unit, Pontifícia Universidade Católica, Porto Alegre, Brazil
Javier Cortés, MD, PhD
Deputy Director, Breast Cancer Program, Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
Paul A. Ellis, MD, FRACP
Professor of Cancer Medicine, Guy's Hospital; King's College, London; Principal Investigator, Sarah Cannon Research Institute, London, United Kingdom

Nadia Harbeck, MD, PhD
Professor, Women's Clinic Breast Center, University of Munich, Munich, Germany
Joseph Gligorov, MD, PhD
Medical Oncologist, Medical Oncology Department, Head of Cancer Coordination Center HUEP, University Cancer Institute, Sorbonne University , Paris, France

Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.

Supported by an independent educational
grant from

Downloadable Slide Kit

HER2-Positive Breast Cancer
Download slides on the available targeted therapies for HER2-positive breast cancer.

Clinical Articles

Steering Committee

Karen A. Gelmon, MD

Karen A. Gelmon, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Roche
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Roche

Carlos H. Barrios, MD

Carlos H. Barrios, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche

Javier Cortés, MD, PhD

Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene Corporation; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Novartis Pharmaceuticals Corporation; Eisai Co., Ltd.; Roche

Paul A. Ellis, MD, FRACP

Paul A. Ellis, MD, FRACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novartis; Pfizer Inc.; Roche; Sanofi-Aventis
Served as a speaker or a member of a speakers bureau for: Roche

Nadia Harbeck, MD, PhD

Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: GlaxoSmithKline; Roche
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Roche

Joseph Gligorov, MD, PhD

Joseph Gligorov, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche; Eisai Co., Ltd.
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Roche
Received grants for clinical research from: Novartis Pharmaceuticals Corporation; Roche; Eisai Co., Ltd.

	What percentage of your patients with early breast cancer receive neoadjuvant treatment?
		<10%
		10%-30%
		30%-50%
		50%-75%
		>75%